Payer & HTA strategy

The access challenge

Even when a therapy clears regulatory hurdles, access can stall. Payers and HTA bodies increasingly expect clarity on comparative effectiveness, humanistic outcomes, and budget consequences—often using evidence standards that differ from those that drove approval. First-in-class and novel modalities face extra friction: limited comparators, immature natural-history data, and uncertainty about long-term benefit. Without a deliberate bridge from the trial program to the access narrative, teams risk a label that cannot be translated into a formulary story, or a dossier that reads like a repackaged CSR.

The cost of misalignment shows up as delayed listings, narrow coverage, prior-authorization friction, and reactive pharmacoeconomic work executed under deadline pressure. We help clients anticipate those decision points and build the evidentiary spine—clinical, patient-reported, economic, and real-world—that holds up under scientific review on both sides of the regulatory and access table.

Where we focus

Value story and endpoint crosswalk

We map registrational endpoints and secondary measures to the outcomes HTAs and PBMs weight in reviews—clinical meaningfulness, functioning, survival where relevant, and caregiver burden where it matters. That includes explicit planning for utility instruments, mapping to generic preference-based measures where appropriate, and honest treatment of surrogate endpoints when long-term data are still immature.

Dossiers, submissions, and scientific engagement

We support structuring and sharpening AMCP-format dossiers, global value documents, and market-specific HTA modules. The emphasis is traceability: every major claim should point to a table, trial, or analysis a reviewer can find without a scavenger hunt. We also prepare teams for scientific advice, clarification cycles, and oral explanation sessions where payer clinicians test whether the narrative matches their population and practice reality.

RWE and evidence of use

Where trials cannot answer access questions, we define RWE options—claims, registries, specialty data—that complement rather than contradict registrational conclusions. We focus on study questions payers actually ask (switching, adherence, sequencing, safety in broader populations) and on governance: transparency, limitations language, and publication plans that protect credibility.

Cross-functional alignment

Medical affairs, HEOR, market access, and clinical development often produce parallel stories. We facilitate workshops and decision logs so pricing, clinical, and value teams share one storyline, with explicit handoffs to economic modeling and post-launch evidence. That reduces last-minute rewrite cycles and prevents field teams from inheriting inconsistent messages.

What we deliver

• Payer-relevant value architecture: hierarchical outcomes, PRO strategy, and plain-language translation of mechanism and benefit for non-specialist reviewers.
• HTA-facing evidence plans by market—NICE, SMC, IQWiG, HAS, and others—integrated with global dossier strategy so local adaptations do not fork the science.
• Dossier and GVD outlines, section logic, and “red team” reviews that simulate payer challenges before submission.
• RWE concept sheets, feasibility assessments, and integration with ICER-style or national health technology reviews where applicable.
• Objection-handler libraries and slide narratives for payer-facing teams, grounded in the same evidence package leadership approves.
• Joint working-session design for medical, access, and stats leads—decisions captured so protocol and post-marketing commitments stay coherent.

Outcomes you can expect

• Earlier visibility into whether your endpoint strategy will survive HTA critique—not a surprise at filing.
• Dossiers and value materials that read as one authored narrative, with fewer ad hoc fire drills before deadlines.
• Clearer trade-offs between trial expansion, RWE investment, and economic substantiation under capital constraints.
• Stronger internal confidence in what the field can claim, and what still requires evidence before the next review cycle.

How we work

lotor lab specializes in programs where precedent is thin. We treat payer and HTA strategy as part of the same constellation as regulatory approval: not identical questions, but connected evidence. We combine clinical rigor with access pragmatism—calling out when a beautiful trial story will fail a budget-impact test, or when an access narrative overreaches beyond the label.

We are hands-on in documents and workshops, not abstract strategy decks. Engagements range from focused reviews of a single submission module to multi-month programs that run alongside Phase 3 design and launch planning. We work with your internal HEOR and medical writers as partners; our role is to tighten logic, surface risks, and keep the thread from protocol to payer intact.

When teams bring us in

• End of Phase 2 or pre–Phase 3, to stress-test endpoints, estimands, and PRO selection against future HTA and PBM questions.
• Pre-submission and launch preparation, when dossiers, pricing rationale, pharmacoeconomic appendices, and field narratives must align under fixed deadlines.
• After regulatory action or major data readouts, to refresh value stories, RWE plans, and access defenses without contradicting the approved label.
• When a prior submission underperformed—appeals, resubmissions, or negotiations—and leadership needs a disciplined reset of the evidence story.